MaxQ AI® Partners with Arterys to Further Expand Global Access to the Company’s Innovative Intracranial Hemorrhage (ICH) Detection Solutions

Radiologists and care providers around the world will have access to MaxQ AI’s ACCIPIO® ICH and Stroke Platform through Arterys’ cloud-native medical imaging platform.

Tel Aviv, Israel and San Francisco, CA – November 13, 2019 – MaxQ AI, the industry-leading medical diagnostic AI company, today announced a new partnership agreement with Arterys, the leader in web-based, AI-powered medical image analysis platform. As part of the agreement, MaxQ AI’s ACCIPIO® ICH and Stroke Platform, which utilizes deep learning technologies to analyze medical imaging data such as non-contrast head CT images, will be available on the Arterys Marketplace. An internet-based medical imaging AI platform for radiology, care providers will have easy access to both MaxQ AI’s FDA Cleared and CE Approved Accipio Ix™ and Accipio Ax™ intracranial hemorrhage (ICH) detection software through the Arterys Marketplace along with future solutions in development for investigational use.

 

“The Arterys Marketplace further expands access to our extensive suite of AI-powered solutions to radiologists through a user-friendly and collaborative platform,” said Gene Saragnese, CEO of MaxQ AI. “This collaboration will help meet the growing demand for AI-powered diagnostic solutions that augment radiologists in acute care settings worldwide. Our Accipio ICH detection solutions for stroke, TBI, and head trauma hold great promise for healthcare through significant quality, clinical, and economic advancement in supporting care providers to make the correct ‘minutes matter’ call.”

 

MaxQ AI’s ACCIPIO® ICH and Stroke Platform provide deep clinical insight and actionable data in minutes that will enable physicians across the world to make faster assessments of stroke, traumatic brain injury, and head trauma in any location, at any time. Accipio Ix enables automatic identification and prioritization of non-contrast head CT images with suspected ICH. Accipio Ax provides automatic slice-level annotation of suspected ICH. Both Accipio Ix and Ax are FDA Cleared and CE Approved. The Accipio platform is comprised of Class II and Class III medical devices with significant clinical evidence.

 

The Arterys Marketplace provides radiologists with high-performance medical imaging viewing, AI-based analysis for interpretation, and collaborative case sharing – all through a web browser. The Marketplace also enables AI software developers and innovators to seamlessly distribute both FDA-cleared clinical applications and earlier-stage AI innovations (for research use only) to clinical environments. The Marketplace offers clinical applications for the analysis of cardiac MR, lung CT, and chest x-ray images – and now non-contrast head CT images due to the partnership with MaxQ AI. Arterys is compliant with patient data privacy regulations and standards, ensuring security in the cloud, and its products are cleared for commercial sale in over 100 countries.

 

“We are excited to have MaxQ AI join the Arterys Marketplace, which was created to expand access to and drive AI-powered innovations in healthcare,” said John Axerio-Cilies, Chief Technology Officer & Founder of Arterys. “MaxQ AI shares our commitment to advance healthcare for everyone, and its powerful and proven Accipio solutions and algorithms will further expand our offerings to the latest cutting-edge AI-driven solutions that are designed to reduce variability and subjectivity in clinical diagnoses and alleviate the burden of growing workloads faced by radiologists.”

 

MaxQ AI will demonstrate the company’s full suite of Accipio solutions during the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting in Chicago (Booth 8345 in the North Hall). MaxQ AI will be highlighted as an Arterys partner at the Arterys exhibit in the AI Showcase (Booth 10918 in the North Hall Level 2).

About MaxQ AI, Ltd.

MaxQ AI is at the forefront of Medical Diagnostic AI. We are transforming healthcare by empowering physicians to provide “smarter care” with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, USA, our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing stroke, traumatic brain injury, and other serious conditions. To learn more, visit www.maxq.ai or follow us on Twitter and LinkedIn.

 

About Arterys, Inc.

Arterys was founded in 2011 to facilitate the global advancement of healthcare and enable insight-driven medicine by leveraging cloud computation and artificial intelligence. Its first major milestone was the first-ever clearance of cloud-based deep learning software for clinical use. Arterys offers a suite of applications for clinicians on the Arterys network via its cloud-based, web-enabled AI medical imaging platform. The Arterys enterprise imaging platform enables use and interaction with deep learning algorithms in real-time, augmenting the clinician workflow, and expediting image interpretation.

 

The company’s mission is to reduce variability and subjectivity in clinical diagnoses and alleviate the enormous workloads radiologists face. With AI, the company is improving the accuracy and consistency in imaging interpretation across practices. Arterys is now leveraging its medical imaging cloud platform to make medical imaging vastly more automated, quantitative and useful. Learn more at https://www.arterys.com/ or follow Arterys on Twitter @ArterysInc and LinkedIn https://www.linkedin.com/company/arterys/.

 

###

 

Media Contact

For MaxQ AI:

Travis Small

617-538-9041

tsmall@sloweymcmanus.com

 

Download PDF